Sickle Cell Disease

Resource Center

Q&As

Expert Q&A

06/16/2023

Lead study author Lana Mucalo, MD, discusses her team’s study examining the prevalence of opioid-related mortality in patients with sickle cell disease from 2013 to 2019. She presented her research at the...

06/16/2023

Research Summaries

FDA Alert

First Gene Therapies Approved to Treat Adult, Pediatric Patients With Sickle Cell Disease

03/19/2024

Jessica Ganga

The FDA approved two gene therapies, the first of their kind, to treat patients aged 12 years and older with sickle cell disease.

03/19/2024

Conference Coverage

COVID-19 Pandemic Had Little Impact on Sickle Cell Disease Outcomes

12/18/2023

Anthony Calabro, MA

In effort to understand the effect of the COVID-19 pandemic among patients with sickle cell disease, researchers compared outcomes and characteristics of hospitalized patients both before and during the...

12/18/2023

Conference Coverage

Conference Coverage

Association Between Sickle Cell Trait and Patients With Leukemia Observed in National Inpatient Sample Study

12/12/2023

Anthony Calabro, MA

In their case-controlled study that utilized the National Inpatient Sample 2016-2019 database, researchers set out to examine the relationship between leukemia and sickle cell trait.

12/12/2023

Research Summary

Global Disease Burden of Sickle Cell Disease 11 Times Higher Than Original Estimates

08/02/2023

Researchers sought to establish the global disease burden of sickle cell disease and its mortality rate.

08/02/2023

sickle cell disease

L-Glutamine for Sickle Cell Disease: A Landmark FDA Approval

08/09/2018

Shaina M. Willen, MD, pediatric hematologist at the Vanderbilt University Medical Center, discusses the recent FDA approval of L-glutamine oral powder for sickle cell disease - the first FDA-approved...

08/09/2018

October 2024

Current Issue

October 2024

Volume 64

Issue 9